Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

26.77 -1.09 (-3.90%)
Streaming Delayed Price Updated: 2:41 PM EDT, Sep 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Delving into NASDAQ:ALKS's Growth Prospects.
High growth, ROE and beating expectations for NASDAQ:ALKS: growth investors may appreciate this. 
Via Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:ALKS is worth considering.
Looking for growth without the hefty price tag? Consider ALKERMES PLC (NASDAQ:ALKS). 
Via Chartmill
When you look at NASDAQ:ALKS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
ALKERMES PLC (NASDAQ:ALKS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
ALKERMES PLC (NASDAQ:ALKS) showing high EPS and FCF growth while beating expectations
Why the growth investor may take a look at NASDAQ:ALKS. 
Via Chartmill
Uber Will Join The S&P 500 Index. The Stock Is Jumping.
The ride-hailing giant will join the index as part of a quarterly rebalancing. 
Via Investor's Business Daily
Topics Stocks
Where Alkermes Stands With Analysts
 
Via Benzinga
NASDAQ:ALKS: good value for what you're paying.
Investors should take notice ofALKERMES PLC (NASDAQ:ALKS)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
NASDAQ:ALKS—A High-Growth Stock Gearing Up for Its Next Upward Move.
Is ALKERMES PLC (NASDAQ:ALKS) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:ALKS is worth considering.
Investors seeking growth at a reasonable cost should explore NASDAQ:ALKS. 
Via Chartmill
Why Is Mural Oncology (MURA) Stock Up 59% Today?
Mural Oncology stock is climbing higher on Friday as the company's shares bounce back from a dip yesterday during its public debut. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
3 Growth Stocks Set to Dominate the Decade
Here are three growth stocks to buy that are poised to dominate the decade. Add them to your portfolio for long-term financial success. 
Via InvestorPlace
7 Healthcare Stocks That Are Poised to Become the Next Unicorns
Discover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments. 
Via InvestorPlace
Why Alkermes Stock Is Sinking Today
The biotech company's Q3 revenue and earnings looked great, but the results weren't enough to wow investors. 
Via The Motley Fool
Why NASDAQ:ALKS Is a Promising High-Growth Stock in the Midst of Consolidation.
ALKERMES PLC (NASDAQ:ALKS), a strong growth stock, setting up for a breakout. 
Via Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:ALKS is worth considering.
ALKERMES PLC (NASDAQ:ALKS) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
NASDAQ:ALKS, an undervalued stock with good fundamentals.
ALKERMES PLC (NASDAQ:ALKS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Why Owens Corning Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with DLQ. 
Via Benzinga
Alkermes Honors Women's Equality Day
Via ACCESSWIRE
Earnings Preview: Alkermes
 
Via Benzinga
Alkermes Q3 Earnings Top Consensus, On Track To Separate Oncology Business, Reaffirms FY23 Outlook
Alkermes PLC (NASDAQ: ALKS) reported Q3 FY23 adjusted EPS of $0.64 compared to $0.02 a year ago, beating the  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
 
Via Benzinga
Alkermes Plummets In Huge Volume. Why One Analyst Says The Reaction Is Overdone.
Analysts say Alkermes' drug is clearly active. But investors have concerns. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
 
Via Benzinga
While growth is established for NASDAQ:ALKS, the stock's valuation remains reasonable.
Looking for growth without the hefty price tag? Consider ALKERMES PLC (NASDAQ:ALKS). 
Via Chartmill
NASDAQ:ALKS is showing good growth, while it is not too expensive.
Despite its growth, ALKERMES PLC (NASDAQ:ALKS) remains within the realm of affordability. 
Via Chartmill
Hovnanian Enterprises, LexinFintech Holdings And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mixed, with the Dow Jones falling around 10 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
3 Top Biotech Stocks Defying the Bear Market
Biotech is still booming, if you pick the right biotech stocks. 
Via The Motley Fool
Alkermes Clocks Over 100% Jump In Q2 Sales and Profits On Reinstated Product Royalty From Long-Acting Invega
Alkermes plc (NASDAQ: ALKS) reported Q2 adjusted EPS of $0.55 compared to $0.06 a year ago, missing the consensus of $0.56 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.